Novartis AG (NYSE:NVS) Shares Acquired by HHM Wealth Advisors LLC

HHM Wealth Advisors LLC boosted its holdings in Novartis AG (NYSE:NVS) by 199.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,502 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. HHM Wealth Advisors LLC’s holdings in Novartis were worth $146,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Union Bancaire Privee UBP SA acquired a new position in shares of Novartis in the 4th quarter valued at $27,000. Legacy Investment Solutions LLC acquired a new position in Novartis in the third quarter valued at $28,000. Fortitude Family Office LLC grew its holdings in shares of Novartis by 503.8% during the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after purchasing an additional 267 shares during the last quarter. Clean Yield Group acquired a new stake in shares of Novartis during the third quarter worth about $43,000. Finally, Brooklyn Investment Group purchased a new stake in shares of Novartis in the 4th quarter valued at about $55,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of research reports. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. StockNews.com cut shares of Novartis from a “strong-buy” rating to a “buy” rating in a report on Friday. BMO Capital Markets upped their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Price Performance

Shares of NYSE NVS opened at $105.54 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.11 and a quick ratio of 0.90. The company has a market cap of $215.72 billion, a PE ratio of 17.95, a P/E/G ratio of 1.51 and a beta of 0.58. The stock has a fifty day moving average price of $100.10 and a 200 day moving average price of $108.43. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Novartis (NYSE:NVS) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.79%. Sell-side analysts forecast that Novartis AG will post 8.34 EPS for the current year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.